BioCentury | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...
BioCentury | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
BioCentury | Jun 22, 2018
Company News

BridgeBio launches mitochondrial-focused subsidiary

...NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NEVPF) to treat Leber’s hereditary optic neuropathy. Fortify will develop compounds derived from NeuroVive's...
...including research funding and potential milestones and single-digit royalties. BridgeBio declined to provide financial terms. NeuroVive...
...Inc., Palo Alto, Calif. BridgeBio Pharma LLC, Palo Alto, Calif. Business: Ophthalmic Elizabeth S. Eaton NVP015 BridgeBio Pharma LLC NeuroVive Pharmaceutical AB Fortify...
BioCentury | Jun 21, 2018
Emerging Company Profile

Getting past PTSD

Neurovation Labs Inc. is developing a GRIA1-targeting tracer and a small molecule therapy that could provide an objective diagnosis of PTSD and treat the underlying disease instead of just its symptoms. Post-traumatic stress disorder (PTSD)...
BioCentury | Jun 18, 2018
Company News

BridgeBio launches mitochondrial-focused subsidiary

...NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NEVPF) to treat Leber’s hereditary optic neuropathy. Fortify will develop compounds derived from NeuroVive's...
...including research funding and potential milestones and single-digit royalties. BridgeBio declined to provide financial terms. NeuroVive...
...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) (see “BridgeBio Launches Rare Genetic Disorder Subsidiary”) . Elizabeth S. Eaton NVP015 BridgeBio Pharma LLC NeuroVive Pharmaceutical AB...
BioCentury | Jun 13, 2018
Distillery Therapeutics

Neurology

...the NAD + precursor in additional animal models of PD. Yungjin Pharmaceutical Co. Ltd. and NeuroVive Pharmaceutical AB...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
BioCentury | Feb 2, 2018
Clinical News

NeuroVive reports preclinical data for cyclophilin D inhibitor program

...a mouse model of lethal mitochondrial myopathy compared with the control group (94% vs. 50%). NeuroVive...
...2020. NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF), Lund, Sweden Product: NVP025 Business: Musculoskeletal Indication: Treat mitochondrial myopathy Allison Johnson NVP025 Karolinska Institute NeuroVive Cyclophilin...
BioCentury | Jan 23, 2018
Distillery Therapeutics

Neurology

...cancer, and solid tumors and Phase I testing for glioblastoma. Yungjin Pharmaceutical Co. Ltd. and NeuroVive Pharmaceutical AB...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...professor at the University of Texas MD Anderson Cancer Center (Houston, Texas). Mitochondrial medicine company NeuroVive Pharmaceutical AB...
Items per page:
1 - 10 of 83
BioCentury | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope...
BioCentury | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
BioCentury | Jun 22, 2018
Company News

BridgeBio launches mitochondrial-focused subsidiary

...NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NEVPF) to treat Leber’s hereditary optic neuropathy. Fortify will develop compounds derived from NeuroVive's...
...including research funding and potential milestones and single-digit royalties. BridgeBio declined to provide financial terms. NeuroVive...
...Inc., Palo Alto, Calif. BridgeBio Pharma LLC, Palo Alto, Calif. Business: Ophthalmic Elizabeth S. Eaton NVP015 BridgeBio Pharma LLC NeuroVive Pharmaceutical AB Fortify...
BioCentury | Jun 21, 2018
Emerging Company Profile

Getting past PTSD

Neurovation Labs Inc. is developing a GRIA1-targeting tracer and a small molecule therapy that could provide an objective diagnosis of PTSD and treat the underlying disease instead of just its symptoms. Post-traumatic stress disorder (PTSD)...
BioCentury | Jun 18, 2018
Company News

BridgeBio launches mitochondrial-focused subsidiary

...NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NEVPF) to treat Leber’s hereditary optic neuropathy. Fortify will develop compounds derived from NeuroVive's...
...including research funding and potential milestones and single-digit royalties. BridgeBio declined to provide financial terms. NeuroVive...
...Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) (see “BridgeBio Launches Rare Genetic Disorder Subsidiary”) . Elizabeth S. Eaton NVP015 BridgeBio Pharma LLC NeuroVive Pharmaceutical AB...
BioCentury | Jun 13, 2018
Distillery Therapeutics

Neurology

...the NAD + precursor in additional animal models of PD. Yungjin Pharmaceutical Co. Ltd. and NeuroVive Pharmaceutical AB...
BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
BioCentury | Feb 2, 2018
Clinical News

NeuroVive reports preclinical data for cyclophilin D inhibitor program

...a mouse model of lethal mitochondrial myopathy compared with the control group (94% vs. 50%). NeuroVive...
...2020. NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF), Lund, Sweden Product: NVP025 Business: Musculoskeletal Indication: Treat mitochondrial myopathy Allison Johnson NVP025 Karolinska Institute NeuroVive Cyclophilin...
BioCentury | Jan 23, 2018
Distillery Therapeutics

Neurology

...cancer, and solid tumors and Phase I testing for glioblastoma. Yungjin Pharmaceutical Co. Ltd. and NeuroVive Pharmaceutical AB...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...professor at the University of Texas MD Anderson Cancer Center (Houston, Texas). Mitochondrial medicine company NeuroVive Pharmaceutical AB...
Items per page:
1 - 10 of 83